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Protein structure elucidation using X-ray crystallography requires both high quality
diffracting crystals and computational solution of the diffraction phase problem.
Novel structures that lack a suitable homology model are often derivatized with
heavy atoms to provide experimental phase information. The presented protocol
efficiently generates derivatized protein crystals by combining random microseeding
matrix screening with derivatization with a heavy atom molecule I3C (5-amino-2,4,6-
triiodoisophthalic acid). By incorporating I3C into the crystal lattice, the diffraction
phase problem can be efficiently solved using single wavelength anomalous
dispersion (SAD) phasing. The equilateral triangle arrangement of iodine atoms in
I3C allows for rapid validation of a correct anomalous substructure. This protocol
will be useful to structural biologists who solve macromolecular structures using
crystallography-based techniques with interest in experimental phasing.
Introduction
In the field of structural biology, X-ray crystallography is
regarded as the gold standard technique to determine
the atomic-resolution structures of macromolecules. It has
been utilized extensively to understand the molecular
basis of diseases, guide rational drug design projects and
elucidate the catalytic mechanism of enzymes1,2 . Although
structural data provides a wealth of knowledge, the process
of protein expression and purification, crystallization and
structure determination can be extremely laborious. Several
bottlenecks are commonly encountered that hinder the
progress of these projects and this must be addressed
to efficiently streamline the crystal structure determination
pipeline.
Following recombinant expression and purification,
preliminary conditions that are conducive to crystallization
must be identified which is often an arduous and time-
consuming aspect of X-ray crystallography. Commercial
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sparse matrix screens that consolidate known and published
conditions have been developed to ease this bottleneck3,4 .
However, it is common to generate few hits from these initial
screens despite using highly pure and concentrated protein
samples. Observing clear drops indicates that the protein
may not be reaching the levels of supersaturation required
to nucleate a crystal. To encourage crystal nucleation and
growth, seeds produced from pre-existing crystals can be
added to the conditions and this allows for increased
sampling of the crystallization space. Ireton and Stoddard first
introduced the microseed matrix screening method5 . Poor
quality crystals were crushed to make a seed stock and then
added systematically to crystallization conditions containing
different salts to generate new diffraction-quality crystals that
would not have otherwise formed. This technique was further
improved by D'Arcy et al. who developed random microseed
matrix screening (rMMS) in which seeds were introduced into
a spare matrix crystallization screen6,7 . This improved the
quality of crystals and increased the number of crystallization
hits on average by a factor of 7.
After crystals are successfully produced and an X-ray
diffraction pattern is obtained, another bottleneck in the form
of solving the 'phase problem' is encountered. During the data
acquisition process, the intensity of diffraction (proportional
to the square of the amplitude) is recorded but the phase
information is lost, giving rise to the phase problem that
halts immediate structure determination8 . If the target protein
shares high sequence identity to a protein with a previously
determined structure, molecular replacement can be used
to estimate the phase information9,10 ,11 ,12 . Although this
method is fast and inexpensive, model structures may not be
available or suitable. The success of the homology model-
based molecular replacement method drops significantly as
sequence identity falls below 35%13 . In the absence of
a suitable homology model, ab initio methods, such as
ARCIMBOLDO14,15  and AMPLE16 , can be tested. These
methods use computationally predicted models or fragments
as starting points for molecular replacement. AMPLE, which
uses predicted decoy models as starting points, struggles
to solve structures of large (>100 residues) proteins and
proteins containing predominately β-sheets. ARCIMBOLDO,
which attempts to fit small fragments to extend into a larger
structure, is limited to high resolution data (≤2 Å) and by
the ability of algorithms to expand the fragments into a full
structure.
If molecular replacement methods fails, direct methods such
as isomorphous replacement17,18  and anomalous scattering
at a single wavelength (SAD19 ) or multiple wavelengths
(MAD20 ) must be used. This is often the case for truly
novel structures, where the crystal must be formed or
derivatized with a heavy atom. This can be achieved by
soaking or co-crystallizing with a heavy atom compound,
chemical modification (such as 5-bromouracil incorporation in
RNA) or labelled protein expression (such as incorporating
selenomethionine or selenocysteine amino acids into
the primary structure)21,22 . This further complicates the
crystallization process and requires additional screening and
optimization.
A new class of phasing compounds, including I3C (5-
amino-2,4,6-triiodoisophthalic acid) and B3C (5-amino-2,4,6-
tribromoisophthalic acid), offer exciting advantages over
pre-existing phasing compounds23,24 ,25 . Both I3C and
B3C feature an aromatic ring scaffold with an alternating
arrangement of anomalous scatters required for direct
phasing methods and amino or carboxylate functional
groups that interact specifically with the protein and provide
binding site specificity. The subsequent equilateral triangular
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arrangement of heavy metal groups allows for simplified
validation of the phasing substructure. At the time of writing,
there are 26 I3C-bound structures in the Protein Data Bank
(PDB), of which 20 were solved using SAD phasing26 .
This protocol improves the efficacy of the structure
determination pipeline by combining the methods of heavy
metal derivatization and rMMS screening to simultaneously
increase the number of crystallization hits and simplify
the crystal derivatization process. We demonstrated this
method was extremely effective with hen egg white lysozyme
and a domain of a novel lysin protein from bacteriophage
P6827 . Structure solution using the highly automated Auto-
Rickshaw structure determination pipeline is described,
specifically tailored for the I3C phasing compound. There
exists other automated pipelines that can be used such as
AutoSol28 , ELVES29  and CRANK230 . Non-fully automated
packages such as SHELXC/D/E can also be used31,32 ,33 .
This method is particularly beneficial to researchers who
are studying proteins lacking homologous models in the
PDB, by significantly reducing the number of screening and
optimization steps. A prerequisite for this method is protein
crystals or a crystalline precipitate of the target protein,
obtained from previous crystallization trials.
Protocol
1. Experimental planning and considerations
1. Use pre-existing crystals of the protein of
interest, preferably generated through vapor diffusion
crystallization. For a generalized protocol of vapor
diffusion crystallization, see Benvenuti and Mangani34 .
Other methods of crystallization such as microbatch
under oil and free interface diffusion will require
harvesting the crystals prior to crushing to generate
microseeds.
2. In the preparation of a seed stock, use the highest
quality crystals that can be sacrificed. The highest quality
crystal can be judged visually based on morphology
or the best diffracting crystal can be selected, if such
data is available. It is very likely that even better quality
crystals are obtained after optimization through seeding.
In the case where no crystals are available, crystalline
precipitate such as spherulites and needles can be used.
3. Identify salt crystals. Salt crystals can grow in
crystallization screens and can look like protein crystals.
Using salt crystals in rMMS will provide no benefit and
will waste precious sample, so it is important to eliminate
salt false positives.
1. Salt crystals are loud when they are crushed.
Crystals must be crushed to generate a seed stock,
so this strategy is particularly relevant. If an audible
crack sound is heard when crushing up the crystals,
the crystal is likely to be salt.
2. If the protein contains tryptophan and tyrosine
residues, use ultraviolet fluorescence microscopy to
identify protein crystals which fluoresce under these
lighting conditions.
3. Use Izit dye (methylene blue) to stain protein crystals
to differentiate them to salt crystals which remain
relatively unstained. However, this procedure is
more destructive and is only recommended if one
has crystals to spare from replicates of the same
drop.
 
NOTE: Although the aforementioned tests may
give promising results, salt crystals may still be
mistaken for protein crystals. In this case, diffraction
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experiments can be used to definitively discern
between a protein and salt crystal.
2. Preparation of lithium I3C stock
1. Measure out 120 mg of I3C (5-amino-2,4,6-
triiodoisophthalic acid) into a 1.5 mL microcentrifuge
tube.
2. Dissolve I3C in 200 µL of 2 M lithium hydroxide. The
solution can be gently heated using a heat block at 40-60
°C to encourage dissolution. The resulting lithium I3C
solution should be brown and has a concentration of 1 M.
 
CAUTION: Lithium hydroxide is corrosive. Safety
glasses, gloves and a lab coat should be worn.
3. Measure the pH of the solution. If necessary, add
small amounts of 1 M hydrochloric acid or 2 M lithium
hydroxide to adjust the pH to between 7 and 8. Add milliQ
water to make the final solution volume to 400 µL. The
concentration of the I3C stock solution is 0.5 M.
 
NOTE: Step 2.3 is optional. The pH of the solution should
be between pH 7-8 prior to any pH adjustment. This step
should be performed if the protein of interest is strongly
affected by pH. The protocol can be paused here. Lithium
I3C can be kept in the dark at 4 °C for at least two
weeks35 .
3. Addition of I3C to the protein stock
1. Method 1
1. Add stock lithium I3C to a 150 µL aliquot of the target
protein. The final concentration should be between
5-40 mM lithium I3C.
2. Method 2 (gentler method)
1. Prepare a protein dilution buffer that matches the
buffer of the target protein. To this dilution buffer, add
stock lithium I3C to give a concentration of lithium
I3C between 10-80 mM.
2. Dilute the protein 1:1 with protein dilution buffer to
give a final concentration of lithium I3C between 5-40
mM.
 
NOTE: Some proteins will precipitate upon coming
into contact with high concentrations of lithium
I3C in method 1, while other proteins can
tolerate it. Method 2 reduces the likelihood of
precipitation. However, this method halves the
protein concentration. For proteins that do not
have an established crystallization protocol, a
protein concentration of 10 mg/mL is generally
recommended for initial crystallization screening.
An initial molar ratio of I3C to protein of 8 is
recommended. Protein concentration and molar
ratio of I3C to protein can be optimized after the initial
screen.
4. Making a seed stock
1. Make a rounded probe for crushing crystals.
1. With a Bunsen burner on the blue flame, heat a
Pasteur pipette towards its middle. Using a tweezer,
pull the end of the Pasteur pipette to draw it out into
a thin diameter of less than 0.3 mm.
2. Once the midsection is thin enough, hold that
segment in the flame to separate the pipette at this
point and round the end of the pipette to finish the
glass probe.
 
NOTE: Rounded probe crystal crushers are sold
by third party vendors. These are an alternative to
making rounded probes.
2. Place five 1.5 mL microcentrifuge tubes on ice.
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3. Under a light microscope, examine the crystallization tray
for a suitable condition to generate microcrystals. Ideally,
good morphology large crystals are selected. However,
this technique also works with poor morphology crystals,
needles, plates, microcrystals and spherulites.
4. Open up the crystallization tray well. For 96 well
crystallization trays sealed with plastic, use a scalpel to
cut the plastic sealing the well. For hanging drop trays
sealed with grease, the coverslip can be removed using
tweezers and inverted onto an even surface.
5. Transfer 70 µL of reservoir solution to a microcentrifuge
tube and chill it on ice. To the other microcentrifuge tubes,
add 90 µL of reservoir solution and return to ice to chill.
 
NOTE: If the reservoir does not have enough volume
or does not exist (in the case of microbatch under oil),
create crystallization reservoir by mixing the appropriate
reagents.
6. Agitate the crystal in the drop using the crystal probe
to thoroughly crush it up. The crystal needs to be
completely crushed up which can be monitored under the
microscope.
7. Remove all the liquid from the drop and transfer it
to the microcentrifuge tube with the reservoir solution.
Mix and subsequently take 2 µL of mixture from the
microcentrifuge tube and add it back to the well. Rinse the
well with the solution and transfer it to the microcentrifuge
tube. Repeat this rinse step once more. From this point
on, keep the microcentrifuge tube cold to avoid melting
the microseeds in the mixture.
8. Vortex the tube at maximum speed at 4 °C for 3 min,
stopping regularly to chill the tube on ice to prevent
overheating.
 
NOTE: Some microseeding protocols add a
polytetrafluoroethylene seed bead to the microcentrifuge
tube to aid crystal crushing7,36 . We have employed the
technique without the use of a seed bead with success,
but see no problems with utilizing a seed bead to crush
up crystals.
9. Make a 1 in 10 serial dilution of the seed stock by
sequentially transferring 10 µL between the chilled
reservoir solutions.
10. Store seed stocks that will not be used immediately at
-80 °C.
5. Setting up an rMMS screen
1. Setting up a 96 well screening plate using a liquid
dispensing robot. In the absence of a robot, a
multichannel pipette may also be used.
1. Transfer 75 µL from a deep well block to a 96 well
crystallization tray. Add 1 µL to the crystallization
drop and 74 µL to the reservoir.
2. Transfer 1 µL of protein supplemented with lithium
I3C, made in step 2, to the crystallization drop.
3. Transfer 0.1 µL of seed stock to the crystallization
drop.
4. Seal the plate with clear sealing tape and incubate
the plate at a constant temperature to allow crystal
growth.
2. Setting up a hanging drop screens
1. Grease the edges of the hanging drop wells (hanging
drop crystallization trays can be found in 24 and 48
well formats).
2. Transfer 500 µL crystallization solution into
reservoir.
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3. Near the center of a glass cover slide, place a 1 µL
drop of protein supplemented with lithium I3C, made
in step 2.
4. Add 1 µL of the crystallization solution to the drop.
5. Transfer 0.1 µL of seed stock to the crystallization
drop.
6. Invert the cover slide and seal the crystallization well
by pushing the cover slide into the grease.
7. Incubate the plate at a constant temperature to allow
crystal growth.
 
NOTE: With new and untested seed stocks, it
is recommended to use the most concentrated
seed stock to maximize the chances of getting
crystallization hits. Subsequent conditions can be
set up with reduced seed concentration to optimize
the number of crystals.
3. Inspect crystal trays under a microscope regularly for
crystal growth. If crystals are of sufficient quality, they
can be harvested for data collection. Crystals can also
be used to generate new seed stocks and new rMMS
screens to allow for iterative optimization.
6. Data collection
1. Harvest crystals using cryoloops, cryoprotect the crystals
and flash cool them in liquid nitrogen. For additional
information on flash cooling crystals, refer to Teng37  and
Garman and Mitchell38 .
1. During the cryoprotection stage, if the crystal is
passed through a new aqueous solution, I3C can
be lost from the crystal due to it leeching into
the cryoprotection solution. Use lithium I3C in
the cryoprotection solution at a concentration that
matches the crystallization condition to mitigate this.
2. Crystals grown using this protocol have successfully
been cryoprotected using Parabar 10312 oil based
cryoprotectant (Hampton Research).
 
NOTE: The protocol can be paused here while
crystals are stored in liquid nitrogen.
 
CAUTION: Liquid nitrogen can cause cold burns.
Liquid nitrogen can also cause asphyxiation if used
in enclosed spaces.
2. Mount the crystal on the X-ray source goniometer and
collect diffraction data using the protocol specific for the
X-ray source.
3. This technique relies on anomalous signal from iodine
atoms in I3C. Thus, select the energy of the X-ray to
maximize this signal.
1. Set synchrotron X-ray sources with tunable energies
as low as possible. For many macromolecular
crystallography beamlines, the lowest configurable
energy is 8000 to 8500 eV.
2. Rotating anode X-ray sources cannot be tuned.
Commonly used anode sources with copper have
the Kα edge at 8046 eV, which provides a good
anomalous signal for iodine (f" = 6.9 e). Anode
sources with chromium have a Kα edge at 5415 eV,
which provides a large anomalous signal for iodine
(f" = 12.6 e).
4. Radiation damage is a significant problem during data
collection as it will degrade the anomalous signal39 .
Select the exposure time and attenuation of the beam
to achieve the best diffraction while minimizing radiation
dose.
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NOTE: In a similar phasing compound with the iodine
atoms replaced with bromine atoms, radiation damage
has been shown to cause the radiolysis of the carbon
bromine bond and a reduction in the occupancy of the
bromine atoms24 .
1. Use inverse beam SAD data collection as a
collection strategy. The data is collected in wedges,
with opposite wedges collected after each other.
This allows Friedel pairs to be collected with
an equivalent dose, resulting in an improved
measurement of anomalous signal less affected by
radiation damage. For example, an eight wedge
strategy to collect 360° would involve collecting
the data in the order of wedge 1 (0°-45°),
wedge 2 (180°-225°), wedge 3 (46°-90°), wedge
4 (225°-270°), wedge 5 (90°-135°), wedge 6
(270°-315°), wedge 7 (135°-180°) and wedge 8
(315°-360°).
 
NOTE: Continuous rotation is an alternative
collection strategy to that of inverse beam data
collection. For a recent comparison of the collection
strategies, see Garcie-Bonte & Katona40 .
7. Data processing and structure solution
1. Perform data reduction on the diffraction data using
XDS41 , with the aim of maximizing the anomalous signal.
Data reduction input parameters are specific to the
dataset and may require some trial and error. Here are
some recommendations to start.
1. Set FRIEDEL'S LAW=FALSE. Execute CORRECT
twice, setting STRICT_ABSORPTION_CORRECT
= TRUE and STRICT_ABSORPTION_CORRECT
= FALSE. One run can have a higher anomalous
signal than the other. Compare the anomalous
signals between the runs using the 'Anomal Corr'
and 'SigAno' disciplines in the output. This provides
an indicator of data quality.
2. Run SHELXC on the XDS_ASCII.HKL file for a
more accurate indication of anomalous signal. The
'Ranom' discipline will give an indication of the
anomalous signal at different resolutions.
2. Run POINTLESS42  and AIMLESS43  to scale the data.
In AIMLESS, set the parameter ANOMALOUS ON. If
the GUI is used, select the option Separate anomalous
pairs for outlier rejection and merging statistics.
Testing different resolution cutoffs may be required to
maximize anomalous signal.
3. Solve the protein structure using Auto-Rickshaw
automated crystal structure determination pipeline44 .
Auto-Rickshaw will attempt to solve the phase problem
and build the crystal structure of the protein automatically
with protein modelling and refinement software.
1. For proteins without a homology model template,
run the SAD protocol of Auto-Rickshaw in Advanced
Mode. Enter the required parameters.
1. Select PROTEIN as the molecule type.
2. Enter the data collection wavelength in
angstroms (Å).
3. Select "I" as substructure element to indicate
iodine atoms was used.
4. Select "i3c" as substructure type to indicate I3C
was the phasing molecule.
5. Select "sub_direct" as the substructure
determination method. This method employs
SHELXD32  to search for the substructure.
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6. Select "3" as the number of expected
substructure per monomer.
7. Enter "1" as the resolution cutoff of
substructure search. This allows Auto-
Rickshaw to automatically determine a suitable
resolution cutoff.
8. Enter the number of residues in a single
monomer, spacegroup of the dataset, and
number of molecules in the asymmetric unit
based on the Matthews coefficient.
9. Select the appropriate dissemination level of
X-ray data that suits the needs. Selecting
"AutoRickshaw developers" will allow Auto-
Rickshaw developers to troubleshoot the run if
problems arise.
10. Input the anomalous data as an mtz file.
11. Input the protein sequence as a seq, pir or
txt file. A seq file can be generated in a text
editor (such as Notepad++9  on Windows or
nano in Linux). Create a new file, enter the
primary sequence of the protein as one long line
or separated by line breaks. Save the file with
the .seq file extension.
12. Enter an institutional email address.
4. Results are delivered via a web-link sent to the email
address provided.
 
NOTE: AutoRickshaw is an automated pipeline
that invokes various crystallography software
packages to solve an X-ray crystal
structure32,33 ,45 ,46 ,47 ,48 ,49 ,50 ,51 ,52 ,53 ,54 ,55 ,56 ,57 ,58 .
If the Auto-Rickshaw run fails to solve the structure,
other Auto-Rickshaw settings can be tested. The
structure determination method can be changed to
"sub_phassade" to use Phaser59  instead of SHELXD32 .
The number of expected substructure per monomer can
be also increased or decreased.
5. During the experimental phasing of the crystal structure,
Auto-Rickshaw will attempt to position heavy atoms in the
unit cell, creating a substructure. The equilateral triangle
arrangement of iodine atoms in I3C presents an efficient
way of validating the substructure. If step 6.3 fails,
validating the substructure could aid in troubleshooting
structure solution.
1. Download the list of heavy atom sites from the Auto-
Rickshaw results page. It is a hyperlink called "heavy
atom sites". This will download a text file with the
heavy atom sites.
2. Change the file extension of the file from .txt to .pdb.
3. Open the PDB file in Coot60 . Turn on symmetry to
see other heavy atoms from neighboring asymmetric
units.
4. Measure the distances between the heavy atoms,
including across asymmetric units. I3C will appear
as an equilateral triangle with a side length of 6
angstroms. The presence of a triangle with these
dimensions indicates the placements of those heavy
atoms are correct.
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Representative Results
Incorporating I3C into rMMS can generate new conditions
supporting derivatized crystal growth
 
The efficacy of simultaneous rMMS screening and I3C
derivatization was demonstrated in two proteins, hen egg
white lysozyme (HEWL, obtained as a lyophilized powder)
and the putative Orf11 lysin N-terminal domain (Orf11
NTD) from bacteriophage P68. Each protein was screened
against PEG/ION HT under four different conditions including:
unseeded, seeded, unseeded with I3C and seeded with
I3C (Figure 1). For both proteins, the sole addition of I3C
did not increase the number of conditions conducive to
crystallization. In the case of Orf11 NTD, only one suitable
condition was identified with and without I3C (Figure 1B).
When I3C was added to the HEWL screens, the number
of hits was reduced from 31 to 26, highlighting the added
complexities of crystallisation when introducing phasing
compounds (Figure 1A). Consistent with other studies,
adding seed to commercial sparse matrix screens to generate
an rMMS screen significantly increased the number of
possible crystallization conditions for both proteins, resulting
in a 2.1 and 6 fold increase for HEWL and Orf11 NTD,
respectively6,61  (Figure 1). Most importantly, simultaneous
addition of I3C and seed increased the number of hits relative
to an unseeded screen, demonstrating a 2.3 and 7 fold
increase for HEWL and Orf11 NTD, respectively. Many of the
crystals from rMMS in the presence of I3C show excellent
crystal morphology (Figure 2).
Seeding allows careful control of crystal number in I3C rMMS
screens
 
In microseeding experiments, the number of seeds
introduced into a crystallization trial can be controlled by
dilution of the seed stock and this allows for precise control of
nucleation in the drop7,36 . This often allows larger crystals to
form since there is reduced competition of protein molecules
at nucleation sites. This advantage also extends to the I3C-
rMMS method and has been demonstrated successfully in
both HEWL and Orf11 NTD. Recreation of a crystallization
condition identified from the I3C-rMMS screen with a diluted
seed stock yielded fewer but larger crystals (Figure 3).
SAD phasing can be used to solve the structures from crystals
derived from rMMS I3C screen
 
Crystals grown using the diluted seed stock shown in Figure
3 were used to solve the structure of the proteins using SAD
phasing using diffraction data from a single crystal (Figure
4). Data was collected on the Australian Synchrotron MX1
beamline62 . Detailed data collection and structure solution
details are described elsewhere27 .
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Figure 1 - rMMS was used to generate new conditions for crystal growth in the presence of I3C for two test proteins.
96 well vapor diffusion crystallization screens were carried out using commercial sparse matrix screens. (A) Hen egg
white lysozyme was tested with the Index HT screen. Trays were seeded with HEWL crystals grown in 0.2 M ammonium
tartrate dibasic pH 7.0, 20% (w/v) polyethylene glycol 3350. (B) Orf11 NTD from bacteriophage P68 was tested with the
PEG/ION screen. Orf11 NTD trays were seeded from crystals from condition G12 from the unseeded screen, shown in
blue. Conditions supporting crystal growth are shown in red. rMMS seeding in the presence and absence of I3C both gave
significantly more crystal hits than unseeded trays. Figure adapted from Truong et al.27 . Please click here to view a larger
version of this figure.
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Figure 2 - Representative images of crystals grown from the vapor diffusion trials shown in Figure 1 (a) and (b).
Figure adapted from Truong et al.27 . Please click here to view a larger version of this figure.
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Figure 3 - Dilution of the seed stock is an effective way to reduce nucleation in a crystallization condition found
using the I3C-rMMS method, to control the number of crystals that form. Reducing nucleation within a drop often results
in crystals growing to larger dimensions. Figure adapted from Truong et al.27 . Please click here to view a larger version of
this figure.
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Figure 4 - Orf11 NTD (PDB ID 6O43) and HEWL (PDB ID 6PBB) were crystallized using the I3C-rMMS method and
solved using Auto-Rickshaw SAD phasing. (A) Ribbon structures of HEWL and Orf11 NTD solved through experimental
phasing. (B) I3C molecule bound to HEWL and Orf11 NTD. (C) Anomalous iodine atoms in I3C are arranged in an
equilateral triangle of 6 Å. Thus the presence of this triangle in the phasing substructure indicates that there is an I3C
molecule in that position. Please click here to view a larger version of this figure.
Discussion
Structure determination of a novel protein in the absence of a
suitable homology model for molecular replacement requires
experimental phasing. These methods require incorporation
of heavy atoms into the protein crystal which adds a level
of complexity to the structure determination pipeline and
can introduce numerous obstacles that must be addressed.
Heavy atoms can be incorporated directly into the protein
through labelled expression using selenomethionine and
selenocysteine. As this method is costly, laborious and
can result in lower protein yields, labelled protein is often
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expressed after crystallization conditions has been found and
optimized with unlabeled protein. Alternatively, crystals can
be derivatized by soaking in a solution containing heavy
atoms22,63 ,64 . This method often uses high quality crystals
and is therefore performed after a robust crystallization
method has already been developed. Successfully obtaining
a derivatized crystal using this method requires further
optimization of soaking procedures and screening of different
phasing compounds, therefore adding more time to an
already laborious process.
Co-crystallization of the protein with the heavy atom can
be performed at the screening stage, thus efficiently
streamlining the process and reducing crystal manipulation
steps that can cause damage. However, there still exists
the potential scenario of obtaining few initial crystallization
hits and the problem of choosing a compatible heavy atom
compound. Many currently available phasing compounds
are incompatible with precipitants, buffers and additives
commonly found in crystallization conditions. They may be
insoluble in sulphate and phosphate buffers, chelate to citrate
and acetate, react unfavorably with HEPES and Tris buffers
or become sequestered by DTT and β-mercaptoethanol21 .
As the I3C phasing compound does not suffer from these
incompatibilities, it is a robust phasing compound that could
be amenable to many different conditions.
In this study, a streamlined method of producing derivatized
crystals ready for SAD phasing through simultaneous co-
crystallization of the I3C phasing compound and rMMS is
presented. The combination of both techniques increases the
number of crystallization hits, with many of the conditions
having improved morphology and diffraction characteristics.
In both Orf11 NTD and HEWL test cases, new conditions
in the I3C-rMMS screen were identified that were absent
when I3C was not present. Potentially, I3C may bind favorably
to the protein, facilitating the formation and stabilization of
crystal contacts27 . In turn, this may induce crystallization
and possibly improve diffraction characteristics. Besides
being a compound compatible with sparse matrix screens,
I3C is also an attractive phasing compound due to its
intrinsic properties. The functional groups that alternate with
iodine on the aromatic ring scaffold allow specific binding
to proteins. This leads to greater occupancy and potentially
reduces background signal23 . Furthermore, the arrangement
of anomalous scatterers in an equilateral triangle is obvious in
the substructure and can be used to rapidly validate binding of
I3C (Figure 4B and 4C). Finally, it can produce an anomalous
signal with tunable synchrotron radiation as well as chromium
and copper rotating anode X-ray sources. Thus, it can be
applied to many different workflows. As I3C is widely available
and inexpensive to purchase, this approach is within reach for
most structural biology laboratories.
There are several experimental considerations that must be
addressed when using the I3C-rMMS method. This method
cannot be applied if initial crystalline material of the protein
cannot be obtained. In difficult cases, crystalline material
from a homologous protein can also be used to generate
seed stock. This cross-seeding approach to rMMS has shown
some promising results7 . Optimizing crystal number through
dilution of the seed stock is a crucial step, which should not be
overlooked, to maximize the chance of producing high quality
large crystals and acquiring suitable diffraction data. If there
are few I3C sites identified in the asymmetric unit, conditions
conducive to crystallization should be further optimized with
an increased concentration of I3C. This may increase the
occupancy of I3C to maximize the anomalous signal and aid
crystal derivatization.
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There can be cases where this technique may not be
the optimal method to derivatize protein crystals. As the
size of a protein or protein-complex increases, the limited
number of I3C sites on the protein surface may not provide
sufficient phasing power to solve the structure. In these
scenarios where protein size is suspected to be impeding
phasing, selenomethionine labelling of the protein may be
a more viable approach to phasing the protein. If the
protein has adequate numbers of methionine residues in
the protein (recommended having at least one methionine
per 100 residues65 ) and high efficiency selenomethionine
incorporation into a protein can be achieved (such as in
bacterial expression systems66 ), multiple high occupancy
selenium atoms will be present in the crystals to phase the
structure.
In addition, some proteins may inherently be unsuited for
derivatization with I3C. I3C binding sites on proteins are
dependent on protein structure. There may exist proteins
that naturally have few exposed patches compatible with
I3C binding. Thus, it is not unforeseeable that there may be
difficulties in co-crystallizing some target proteins with I3C.
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